Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure

Journal of the American College of Cardiology

Volumn 33, Issue 5, 1999, Pages 1174-1181

  Havranek, Edward P ^a,i   Thomas, Ignatius ^a   Smith, William B ^a,e   Ponce, George A ^a   Busker, Martin ^b,f   Munger, Mark A ^c,g   Wolf, Robert A ^d,h  

^a Health Sciences Center ^*

^b UNIVERSITY OF COLORADO   (United States)

^c Slidell Memorial Hospital   (United States)

^d Louisiana Cardiovascular Research Center   (United States)

^e Adult Cardiovascular Disease   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; IRBESARTAN; LISINOPRIL; NORADRENALIN; PLACEBO; QUINAPRIL; RAMIPRIL; RENIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION TIME; HEART RATE; HUMAN; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; MULTICENTER STUDY; NORADRENALIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UREMIA;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; SAFETY; SINGLE-BLIND METHOD; TETRAZOLES; TREATMENT OUTCOME;

EID: 0033117190     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00695-0     Document Type: Article

References (22)

1. Sweet CS, Rucinska EJ. Losartan in heart failure: preclinical experiences and initial clinical outcomes. Eur Heart J 1994;15 Suppl D:139-44.
2. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-9.
3. Crazier I, Ikram H, Awan N, et al. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995;91: 691-7.
4. Cody RJ. Angiotensin-converting enzyme inhibitors: mechanisms, pharmacodynamics, and clinical trials in heart failure. Cardiol Rev 1994;2:145-56.
5. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273: 1450-6.
6. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
7. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
8. Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997;80:219-27.
9. Skidgel RA, Erdös EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens 1987;A9:243-59.
10. Fogari R, Zoppi A, Tettamanti F, Malamani GD, Tinelli C, Salvetti A. Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomized, cross-over study. J Cardiovasc Pharmacol 1992;19:670-3.
11. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995;26:438-45.
12. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993;265:826-34.
13. 1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994;251:143-50.
14. Marino MR, Langenbacher KM, Ford NF, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin II blocker irbesartan. Clin Drug Invest 1997;14:383-91.
15. Chomsky DB, Lang CC, Rayos GH, et al. Hemodynamic exercise testing. A valuable tool in the selection of cardiac transplantation candidates. Circulation 1996;94:3176-83.
16. Szlachcic J, Massie BM, Kramer BL, Topic N, Tubau J. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol 1985;55:1037-42.
17. Pool JL, Guthrie RM, Littlejohn TW III, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998;11:462-70.
18. Reeves RA, Lin C-S, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998;31:1311-6.
19. Lejemtel T, Awan N, Liang C, et al. Irbesartan - a new angiotensin II antagonist: acute hemodynamic effect in patients with heart failure. Circulation 1996;94 Suppl:3643-4.
20. Baruch L, Anand IS, Judd DL, Cohn JN. Hemodynamic response to AT1 receptor blockade with valsartan in ACE inhibitor-treated patients with heart failure [abstract]. Circulation 1996;94 Suppl 1:I-428.
21. Vijay N, Alhaddad IA, Denny DM, et al. Irbesartan compared with lisinopril in patients with mild to moderate heart failure [abstract]. J Am Coll Cardiol 1998;31 Suppl A:188A.
22. Tonkon M, Awan N, Niazi I, et al. Evaluation of irbesartan in combination with conventional therapy, including angiotensin converting enzyme inhibitors, in heart failure [abstract]. J Am Coll Cardiol 1998;31:188A.